For over 35 years, she has been a passionate advocate for expanding family planning options and access, and she currently directs a broad research program to develop and introduce new, innovative contraceptives that will better meet the changing needs of women throughout their reproductive lives.
As a leader and mentor, Dr. Dorflinger brings a unique lens to contraceptive R&D through her breadth of experience, from product concept and formulation to clinical trials, product registration, and post-marketing introductions to family planning program research in resource-constrained areas of the world.
Dr. Dorflinger has held a variety of leadership positions at FHI 360, including Vice President of Clinical Research, Vice President of Research and Development, Director of Clinical Trials, and Director of Regulatory Affairs and Quality Assurance. Before joining FHI 360, she spent seven years at USAID managing programs supporting the development, introduction, and post-marketing assessments of contraceptive technologies.
Dr. Dorflinger received her undergraduate degree in chemistry from Lafayette College, a PhD in physiology from Yale University, and did post-doctoral training at the Harvard School of Public Health. She has received noteworthy awards, including the Science and Technology in Development award from USAID, the George Washington Kidd Award for career distinction, and an honorary Doctor of Sciences from Lafayette College, her alma mater. She is the author or co-author of over 55 scientific publications.
